RNAZ_OUT_1 [2025-04-01 13:31:42 -0400] 2327 Bytes | 651 tokens | Cum: 651 tkns (8.14% of 8k)
==========================================================================

Alright, let’s light it up, because it's 1:31:41 PM on Tue Apr 01, 2025 -0400, and I'm charging into TransCode Therapeutics (RNAZ), popping from 0.495 to 0.5911. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

Here's the first list of news for TransCode Therapeutics:

C1 - Mar-27-25 04:37PM - TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138
C2 - Mar-25-25 06:24PM - TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
C3 - Mar-23-25 11:11PM - TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
C4 - Mar-14-25 08:35AM - SRC approves opening of TransCodes fourth cohort in trial of TTX-MC138
C5 - Mar-13-25 07:47AM - TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial
C6 - Feb-25-25 04:15PM - TransCode Therapeutics, Inc. Announces Results of Special Meeting
C7 - Feb-06-25 08:00AM - TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
C8 - Feb-04-25 04:15PM - TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

Prior AI Reports for RNAZ:
1. 2025-03-21 – Score: 10 – Target: 1.1500 – Highs: 1.6700 / 0.7700 / 0.72
transcode-therapeutics-struggles-amid-high-short-interest-and-negative-returns

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on TransCode Therapeutics (RNAZ)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

RNAZ_OUT_3 [2025-04-01 13:31:46 -0400] 1100 Bytes | 304 tokens | Cum: 957 tkns (11.96% of 8k)
==========================================================================

Showing C1 (chunk 1 of 9): C1:
**TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138**
Date: Mar-27-25 04:37PM
Source: (PR Newswire)
URL: https://www.prnewswire.com/news-releases/transcode-therapeutics-announces-initial-dosing-in-fourth-cohort-of-phase-1-clinical-trial-with-ttx-mc138-302413679.html

BOSTON,March 27, 2025/PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of its Phase I clinical trial has received their initial dose. TransCode also reported that two additional patients in Cohort 4 are scheduled to receive TTX-MC138. The therapeutic candidate being evaluated, TTX-MC138, is TransCode's lead candidate designed to inhibit microRNA-10b, a microRNA critical to the emergence and progression of metasta

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RNAZ_OUT_5 [2025-04-01 13:31:47 -0400] 1026 Bytes | 308 tokens | Cum: 1365 tkns (17.06% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-28T12:05:48Z - 12 Health Care Stocks Moving In Friday's Pre-Market Session - Dermata Therapeutics (NASDAQ:DRMA), DB...
A2 - 2025-03-28T09:58:00Z - Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Alta Equipm...
A3 - 2025-03-28T08:44:44Z - PRTG Soars On Mesothelioma Data, NVNO Awaits FDA Decision, CureVac Jumps On Patent News...
A4 - 2025-03-28T00:35:10Z - TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-...
A5 - 2025-03-27T21:05:49Z - 12 Health Care Stocks Moving In Thursday's After-Market Session - Equillium (NASDAQ:EQ), Edap TMS (N...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

RNAZ_OUT_7 [2025-04-01 13:31:54 -0400] 1098 Bytes | 337 tokens | Cum: 1704 tkns (21.30% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Friday's Pre-Market Session - Dermata Therapeutics (NASDAQ:DRMA), DBV Technologies (NASDAQ:DBVT)**Date: 2025-03-28Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44534298/12-health-care-stocks-moving-in-fridays-pre-market-sessionGainers Portage Biotech PRTG stock rose 158.8% to $12.19 during Friday's pre-market session. The market value of their outstanding shares is at $20.0 million. Lexicon Pharmaceuticals LXRX stock rose 106.53% to $0.72. The company's market cap stands at $259.5 million. DBV Technologies DBVT shares moved upwards by 61.12% to $6.3. The company's market cap stands at $129.2 million. Prelude Therapeutics PRLD shares increased by 17.14% to $0.8. The company's market cap stands at $44.0 million. TransCode Therapeutics RNAZ stock moved upwards by 15.59% to $0.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RNAZ_OUT_9 [2025-04-01 13:31:55 -0400] 915 Bytes | 281 tokens | Cum: 2159 tkns (26.99% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-07-23T17:26:37Z - Why Transcode Therapeutics (RNAZ) Stock Is Down 60% - Benzinga
B2 - 2024-06-10T12:07:00Z - Beat the Market Like Zacks: Goldman Sachs, Micron, Amgen in Focus
B3 - 2024-06-10T11:00:00Z - Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
B4 - 2024-05-29T13:15:00Z - TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
B5 - 2024-05-12T10:18:00Z - Successful Penny Stocks Trader Tips, 3 To Use
B6 - 2024-04-03T13:10:00Z - TransCode Therapeutics Reports 2023 Results; Provides Business Update

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

RNAZ_OUT_11 [2025-04-01 13:31:58 -0400] 706 Bytes | 198 tokens | Cum: 2359 tkns (29.49% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Why Transcode Therapeutics (RNAZ) Stock Is Down 60% - Benzinga**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/24/07/39913968/why-transcode-therapeutics-rnaz-stock-is-down-60Transcode Therapeutics (RNAZ) stock is trading 62% lower after the company announced the pricing of a public offering of 10 million shares at $0.30 per share, aiming to raise $3 million. The funds will be used for product development, including clinical trials for their lead therapeutic candidate.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RNAZ_OUT_13 [2025-04-01 13:31:59 -0400] 1123 Bytes | 294 tokens | Cum: 2721 tkns (34.01% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-25 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On March 23, 2025, TransCode Therapeutics, Inc., a Delaware corporation (the Company), entered into a Placement Agency Agrmt (the Agrmt) with ThinkEquity LLC (the Placement Agent), pursuant to which the Company agree...

S2 - 2024-12-02 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On November 26, 2024, TransCode Therapeutics, Inc. (the Company ) entered into a securities purchase agreement (the Purchase Agrmt ) with certain accredited investors, pursuant to which the Company agreed to sell and iss...

S3 - 2024-12-02 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On November 26, 2024, TransCode Therapeutics, Inc. (the Company ) entered into a securities purchase agreement (the Purchase Agrmt ) with certain accredited investors, pursuant to which the Company agreed to sell and iss...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

RNAZ_OUT_15 [2025-04-01 13:32:02 -0400] 1098 Bytes | 281 tokens | Cum: 3004 tkns (37.55% of 8k)
==========================================================================

Showing S1 (chunk 1 of 4): S1:
Item 1.01 Entry into a Material Definitive Agreement.

On March 23, 2025, TransCode Therapeutics, Inc., a Delaware corporation (the Company), entered into a Placement Agency Agreement (the Agreement) with ThinkEquity LLC (the Placement Agent), pursuant to which the Company agreed to issue and sell, directly to various investors, in a registered direct offering (the Offering), an aggregate of 10,250,000 shares (the Shares) of the Companys common stock, par value $0.0001 per share, (the Common Stock) and 10,250,000 Common Warrants (the Common Warrants) to purchase 10,250,000 shares of Common Stock, at an aggregate offering price of $0.98 per share of Common Stock and accompanying Common Warrant. Additionally, as part of its compensation for acting as placement agent for the Offering, the Company also agreed to issue to the Placement Agent, warrants to purchase 512,500 shares of Common

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RNAZ_OUT_17 [2025-04-01 13:32:15 -0400] 4160 Bytes | 1197 tokens | Cum: 4296 tkns (53.70% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+-----------------------+
| Volume: 3,129,701 | Perf Month: -71.41% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+------------------------+-----------------------+
| Avg Volume: 7.18M | Perf Quarter: -85.04% | Short Float: 1.62% | ROE: -490.03% |
+--------------------+-----------------------+------------------------+-----------------------+
| Rel Volume: 0.73 | Index: - | Short Ratio: 0.05 | ROI: -903.45% |
+--------------------+-----------------------+------------------------+-----------------------+
| RSI (14): 28.77 | Market Cap: 12.81M | Short Interest: 0.34M | Sales Surprise: 0.00% |
+--------------------+-----------------------+------------------------+-----------------------+
| ATR (14): 0.53 | Shs Outstand: 23.34M | Beta: 1.52 | EPS Surprise: 0.00% |
+--------------------+-----------------------+------------------------+-----------------------+
| SMA20: -40.32% | Shs Float: 20.98M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+-----------------------+
| SMA50: -88.45% | Inst Own: 0.78% | Sales past 5Y: 0.00% | Earnings: Mar 28 |
+--------------------+-----------------------+------------------------+-----------------------+
| SMA200: -95.48% | Insider Own: 10.11% | Employees: - | |
+--------------------+-----------------------+------------------------+-----------------------+
| Perf Week: -20.82% | Insider Trans: 0.00% | Debt/Eq: 0.09 | |
+--------------------+-----------------------+------------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -17905135.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.587716
Average Volume: 15063789.82
30-Day High: 1.92
30-Day Low: 0.49

[Detailed Financials: Q2 2024]
- Total Assets: $4,824,588.0
- Total Liabilities: $3,502,314.0
- Total Equity: $1,322,274.0
- Current Assets: $4,386,421.0
- Current Liabilities: $3,502,314.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.74

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-1,559,125.0

[Detailed Financials: Q1 2024]
- Total Assets: $7,290,467.0
- Total Liabilities: $2,706,172.0
- Total Equity: $4,584,295.0
- Current Assets: $6,714,022.0
- Current Liabilities: $2,706,172.0

[Income Statement: Q1 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.65

[Cash Flow Statement: Q1 2024]
- Net Cash Flow: $2,146,078.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

RNAZ_OUT_19 [2025-04-01 13:32:17 -0400] 676 Bytes | 167 tokens | Cum: 4731 tkns (59.14% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

RNAZ_IN_21 [2025-04-01 13:32:17 -0400] 126 Bytes | 29 tokens | Cum: 4788 tkns (59.85% of 8k)
==========================================================================

====================================
[2025-04-01 13:32:17] # Analysis Completed
Elapsed Time: 36.23 seconds